Krystal Biotech Inc (KRYS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Krystal Biotech Inc (KRYS) has a cash flow conversion efficiency ratio of 0.055x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($74.79 Million) by net assets ($1.36 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KRYS stock market capitalisation for the company's overall valuation and market capitalisation.
Krystal Biotech Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Krystal Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Krystal Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Krystal Biotech Inc ranked by their cash flow conversion efficiency. Explore KRYS operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jinduicheng Molybdenum Co Ltd
SHG:601958
|
0.073x |
|
AvalonBay Communities Inc
NYSE:AVB
|
0.030x |
|
Donaldson Company Inc
NYSE:DCI
|
0.080x |
|
Mazagon Dock Shipbuilders Limited
NSE:MAZDOCK
|
0.004x |
|
Getlink SE
PA:GET
|
0.135x |
|
Advanced Drainage Systems Inc
NYSE:WMS
|
0.020x |
|
Jyske Bank A/S
CO:JYSK
|
-0.328x |
|
RYOHIN UNSP.ADR/1
F:3RKU
|
N/A |
Annual Cash Flow Conversion Efficiency for Krystal Biotech Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Krystal Biotech Inc from 2016 to 2025. View Krystal Biotech Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.22 Billion | $200.87 Million | 0.165x | +26.29% |
| 2024-12-31 | $946.38 Million | $123.42 Million | 0.130x | +214.35% |
| 2023-12-31 | $778.64 Million | $-88.80 Million | -0.114x | +40.78% |
| 2022-12-31 | $522.23 Million | $-100.57 Million | -0.193x | -138.45% |
| 2021-12-31 | $593.58 Million | $-47.94 Million | -0.081x | +9.56% |
| 2020-12-31 | $292.08 Million | $-26.08 Million | -0.089x | +3.17% |
| 2019-12-31 | $202.91 Million | $-18.71 Million | -0.092x | -10.55% |
| 2018-12-31 | $113.23 Million | $-9.45 Million | -0.083x | -6.09% |
| 2017-12-31 | $49.47 Million | $-3.89 Million | -0.079x | +98.27% |
| 2016-12-31 | $289.00K | $-1.31 Million | -4.536x | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystro… Read more